Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Our key takeaways from ISMPP EU 2026 – Evolving with Purpose: Excellence in an Era of Efficiency

April 13, 2026 |  

Explore Inizio Medical’s key takeaway from ISMPP EU 2026, including AI governance, transparency, patient partnership and evolving impact measurement.

- PMLiVE

Medical publications are navigating a period of rapid change. From artificial intelligence and automation to transparency, governance, patient partnership, and evolving impact measurement, the pressure to deliver faster must now coexist with the responsibility to maintain scientific rigour and trust. 

Inizio Medical’s ISMPP EU 2026 Insights Report captures the most consequential discussions from the meeting and outlines the emerging strategic implications for publication teams. 

More than just a meeting summary, this is Inizio Medical’s informed perspective on how publication practices are evolving and how teams can adapt to ensure they remain efficient, ethical, and impactful in 2026 and beyond. 

Download the full report here. 

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development

Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and...

Infographic: Therapy Watch Acute Myeloid Leukemia market snapshot

This Acute Myeloid Leukemia infographic offers a snapshot of the real-world patient insights collected by our Therapy Watch study, based on data collected from a panel of 220 physicians across...

Navigating the future of AI: Insights from EphMRA’s one day meeting in London

Authored by: Ellie Forde and Mark Braund, Directors

Research conducted for Johnson and Johnson published in scientific journal

Findings from a study conducted by Dr. Chris Gaj, Vice President at Research Partnership, has been published in Clinical Genitourinary Cancer.

Connecting our Inizio Advisory capabilities to help a client address a threat to the brand, guide strategy and improve brand performance

The challenge Our client knew that prescribing of a key brand in a major market had slowed and needed to understand which patient segments were impacted so they could address...

Autoimmune conditions: Living With syndicated patient reports

The prevalence of autoimmune conditions is increasing, and despite significant advancements in treatments, individuals affected by these diseases may not be receiving the most effective management and care. In our...

How we elevated HCP market research engagement and insights using AI avatars for an immersive experience

Our client required an effective strategy for promoting discussions about self-paid vaccines with healthcare professionals (HCPs) during patient consultations. The conventional method of conducting market research would typically only deliver...

How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution

PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such...

The risk of replicating social bias in synthetic patient data – The need for human intelligence partnered with AI

Authored by Paul Reed and Anabelle Gall

Latest European developments and new talent at Research Partnership

Angela Duffy has been appointed as Managing Director for our European based ad hoc research teams. Angela has been an integral part of Research Partnership for 19 years, witnessing its...